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PreviewsDo the regulatory plasmablasts
described here match those previously
described by Shen et al. (2014)? Pheno-
typically, there are a number of similarities
between the regulatory plasmablasts of
Matsumoto et al. (2014) and Shen et al.
(2014); both groups described them as
CD138+CD44hiCXCR4+ and possibly ex-
pressing IgM. However, a discrepancy
exists in their mechanism of action. Shen
et al. (2014) report a role for IL-35 produc-
tion by regulatory plasmablasts whereas
Matsumoto et al. (2014) could not detect
IL-35 expression, either directly ex vivo
or after brief PMA and ionomycin stimula-
tion in vitro. The difference is difficult to
reconcile because both groups used the
same model of EAE and both isolated
their cells at day 14 after EAE induction.
The difference might reflect the fact that
Shen et al. (2014) focus on splenic
CD138+ plasma cells, whereas Matsu-
moto et al. (2014) focus on CD138+CD44hi
plasmablasts in the dLN. Perhaps then
the IL-35+ regulatory plasma cells act
centrally and only IL-10+ regulatory880 Immunity 41, December 18, 2014 ª2014plasma cells are found in inflamed lymph
nodes.
In conclusion, Matsumoto et al. (2014)
have provided new evidence suggesting
that Pax5+ Breg cells can differentiate
into plasmablast Breg cells that up-
regulate IL-10 production as a result of
IRF4 transcription. These findings rein-
force the note of caution needed when
designing new B cell and/or plasma-
cell-directed therapies for the treatment
of patients with autoimmune diseases
or transplant recipients. Indiscriminate
elimination of all plasmablast cells might
lead to unexpected results due to the
depletion of regulatory plasmablasts
as well as autoreactive B cells and/or
plasmablasts.REFERENCES
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Although interleukin-17A (IL-17A) facilitates colon cancer development, its target cells remain elusive. In this
issue of Immunity, Wang et al. (2014) now demonstrate that IL-17A receptors on the intestinal epithelium
promote progression of APC mutant adenomas associated with IL-6 expression and that IL-17A confers
chemotherapy resistance.The interleukin-17 (IL-17) family of cyto-
kines is widely recognized for its ability
to modulate inflammatory responses.
Among the six IL-17 family members,
IL-17A and IL-17F are best understood
within lymphocyte populations. IL-17A
and IL-17F share similar expression
patterns and bind as ligand homo- or het-
erodimers to dimeric IL-17RA-IL-17RC re-
ceptor complexes to induce host defense
responses against bacterial pathogensat epithelial and mucosal barriers of the
skin, lung, and the colon (Gaffen, 2009).
In this issue of Immunity, Wang et al.
(2014) describe a mechanism by which
epithelial IL-17RA expression enables the
IL-17A-dependent progression of colon
tumors via IL-6 signaling, and they identify
IL-17A expression as a potential mecha-
nism of resistance to chemotherapy.
IL-17 cytokines are produced primarily
by mucosal lymphocytes, including natu-ral killer (NK) cells, CD4+ T helper 17
(Th17) cells, gd Tcells, and innate lym-
phoid cells (ILC), and by some nonhemo-
poietic cells, including the Paneth cells
of the small intestine. For the majority of
lymphocytes, IL-17 expression is contin-
gent on the transcription factors STAT3
and RORgt and the concerted activities
of IL-6 and transforming growth factor-b
(TGFb), and the phenotype of IL-17A
producing Th17 and ILC3 cells is
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Previewsreinforced by IL-23 (Gaffen, 2009). Thus,
many autoimmune diseases, such asmul-
tiple sclerosis, rheumatoid arthritis, in-
flammatory bowel disease, psoriasis,
and allergic airway inflammation, are
characterized by dysregulated IL-17A,
IL-17F, and IL-23 production. Accord-
ingly, therapeutic antibodies directed
against IL-12-IL-23 (e.g., Ustekinumab),
IL-17A (e.g., Secukinumab), or IL-17RA
(e.g., Brodalumab) show considerable
clinical benefit for patients affected by
psoriasis and rheumatoid arthritis and
are now being trialed for other inflamma-
tory conditions.
A tumor-promoting role for the IL-23-
IL-17 cytokine signaling axis has been
identified for both inflammation-asso-
ciated and sporadic cancers of the liver,
stomach, and colon (Yang et al., 2014),
and both cytokines are elevated in the
early stages of human disease and exac-
erbate tumor formation in mouse models.
Wang et al. now identify mature intestinal
enterocytes as the IL-17RA-expressing
cell population that facilitates the progres-
sion of colonic tumors in mice, although
IL-17RA is also widely expressed on
myeloid cells and fibroblasts. Meanwhile,
IL-17RC is more commonly found on the
surface of tissue-resident immune cells
and, at least in humans, has a higher bind-
ing activity for IL-17F than for IL-17A
(Gaffen, 2009). However, genetic loss of
either IL-17RA or IL-17RC completely
abolishes the cellular response to both
cytokines, which otherwise result in re-
ceptor-mediated engagement of Act1
and Traf6, and activation of the MAPK-
ERK and canonical NF-kB pathways
(Gaffen, 2009).
In the colon cancer model used by
Wang et al., adenomas arise from sponta-
neous loss-of-heterozygosity of the tumor
suppressor Apc in an engineered back-
ground of heterozygous Apc ablation in
the colonic epithelium. In humans, bial-
lelic mutations in APC within the rapidly
proliferating intestinal stem cells account
for the initiating event in more than
80% of sporadic colon cancers, and the
monoallelic mutation underpins familial
adenomatous polyposis syndrome. Con-
sistent with a pro-tumorigenic role for
IL-17A, Wang et al. report that systemic
IL-17RA ablation in these mice impaired
tumor cell proliferation, reduced STAT3
and NF-kB activation, and increased
tumor cell apoptosis. Although Wanget al. also found attenuated inflammation
in the absence of IL-17RA expression,
neither blood nor lymph-vessel formation
were altered, nor was transcription of in-
testinal stem cell markers, suggesting
that IL-17A might act on mature entero-
cytes or other cells in the tumor microen-
vironment. Using reciprocal bone-marrow
chimeras, Wang et al. discovered that
the tumor-promoting activity of IL-17RA
was not mediated by hematopoietic cells,
but rather by the host radio-resistant
cells. These observations were corrobo-
rated by specific ablation of IL-17RA in
colonic epithelial cells via a conditional
Il17ra allele. Wang et al. verified a direct
effect of IL-17A on enterocytes by stimu-
lating organoids derived from Apc-defi-
cient intestinal crypts with recombinant
IL-17A, which resulted in activation of
the NF-kB and MAPK signaling cascades
and only minimal engagement of STAT3.
In these organoids, IL-17A stimulation
did not alter the excessive nuclear b-cate-
nin accumulation that results from the
loss of APC function. This observation
suggests that IL-17RA signaling in the
transformed mucosa regulates tumor
cell proliferation independently of the
aberrantly activated WNT-b-catenin sig-
naling cascade and is akin to findings
obtained in mice with impaired respon-
siveness of APC mutant neoplastic
epithelium to IL-6 and IL-11 (Phesse
et al., 2014; Putoczki et al., 2013).
Wang et al. link their in vivo observa-
tions to the ability of IL-17A to dampen
the antitumor immune response of regu-
latory T cells and to induce the production
of IL-6 and other inflammatory cytokines
and chemokines. Indeed, they confirm
that IL-6 deficiency reduced colonic
tumor burden in their mouse model and
that IL-17RA ablation in colonic epithelial
cells reduced IL-6 expression in the
tumors without altering expression of
IL-17A or RORgt. These findings suggest
that during the formation of APC mutant
adenomas, the NF-kB target IL-6, via
activation of STAT3, facilitates tumor cell
survival, proliferation, and angiogenesis
and acts down-stream of IL-17A (Fig-
ure 1). Surprisingly, IL-17RA-deficient
tumors retained elevated expression of
IL-11, the STAT3 activating cytokine,
which most prominently supports the
growth of APC mutant adenomas (Pu-
toczki et al., 2013) and, alongside the
elevated IL-1b observed by Wang et al.,Immunity 41, Dpotentially promotes RORgt and IL-17A
expression in IL-17RA-deficient tumors.
Given the additive effects of IL-6 and IL-
11, it remains tempting to speculate that
the reduced tumor formation observed
by Wang et al. in mice with enterocyte-
specific IL-17RA ablation might be further
impaired if one were to simultaneously
also interfere with IL-11 signaling.
Thus far, IL-17A has been primarily
associated with intestinal tumorigenesis
in situations of chronic inflammation or
commensal bacteria-associated infec-
tion (Hyun et al., 2012; Wu et al., 2009).
Because bacterial stimulation of submu-
cosal sentinels results in activation of
the IL-23-IL-17 innate defense response,
neutralization of these cytokines can also
aggravatedextran sulfate sodium-induced
colitis inmice (Ogawa et al., 2004). The ob-
servations by Wang et al. now suggest
that this might be the consequence of
impaired epithelial restitution mediated by
IL-17RA-dependent NF-kB activation in
enterocytes, and these findings are akin
to similar observations involving impaired
gp130-receptor-dependent STAT3 activa-
tion. Accordingly, even in the context of
sporadic colon cancer, neoplastic cells
might have evolved to thrive on IL-17-IL-
23 wound-healing mechanisms, given
that APC mutations decrease mucosal
barrier integrity and thus lead to the release
of IL-23 and IL-17 by submucosal immune
cells and the subsequent growth pro-
motion of the transformed epithelium
(Grivennikov et al., 2012).
Using a model of synchronized Apc
loss, Wang et al. observed a concomitant
increase in tumor-derived IL-17A, IL-17C,
and IL-17F and found that tumor initiation
was reduced in mice that lacked epithelial
IL-17RA expression or that had been
treated with a neutralizing IL-17A anti-
body. Long-term administration of this
antibody reduced the growth of estab-
lished adenomas and enabled apoptosis
and tumor shrinkage in response to
5-fluorouracil, which is one component
in the chemotherapy cocktail currently
used for the treatment of colon cancer.
Whether therapeutic IL-17A inhibition
in metastatic colon cancers, which are
more clinically relevant, confers similar
benefits remains to be established. This
is particularly relevant in light of the
findings that B16 melanoma and MC38
colon cancer cell lines show increased
lung metastasis in the absence ofecember 18, 2014 ª2014 Elsevier Inc. 881
Figure 1. IL-17-Dependent Signaling Facilitates Growth of APCMutant Tumors but Is Dispensable for Homeostatic Renewal of the Colonic
Mucosa
Continuous renewal of the normal intestinal mucosa in the adult is governed by the Wnt-b-catenin pathway, which is negatively regulated by the APC tumor sup-
pressor gene (left). In contrast, in cancer cells with excessive Wnt-b-catenin pathway activation downstream of homozygous APC-impairment mutations (right),
Wang et al. now show that the growth of corresponding tumors requires IL-17A-dependent activation of the IL-17RA receptor on the neoplastic epithelium. At
least part of this effect is attributed to NF-kB-associated IL-6 induction, which also facilitates the growth of APC mutant cells via the gp130 receptor-Stat3
pathway. Engagement of the later by the related IL-11 cytokine also promotes the growth of APC tumors, albeit independently of IL-17 signaling. IL-17 is pro-
duced by various submucosal immune cells, which require phenotype stabilization through IL-23 released from activated innate sentinel cells.
Immunity
PreviewsIL-17A, possibly as a result of an impaired
CD8 anti-tumor immune response (Mar-
tin-Orozco et al., 2009).
The work by Wang et al. expands our
knowledge of IL-17 signalingmechanisms
in colorectal cancer and might inform
future studies that focus on patient strat-
ification for therapeutic treatments. Given
that radiotherapy and chemotherapy
remain the standard-of-care for colorectal
cancer patients, it will be interesting to
correlate the amount of therapy-induced
damage to the nontransformed mucosa
with IL-17 production and disease relapse
and/or progression. It might be possible
to mitigate the negative impact of anti-IL-
17A-IL-17RA therapy on mucosal restitu-
tion by staggering neoadjuvent IL-17A-
IL-17RA treatment with chemotherapy. It
also remains to be seen whether IL-22
and other IL-23-induced cytokines can882 Immunity 41, December 18, 2014 ª2014functionally substitute for IL-17A and
result in acquired resistance to long-term
anti-IL-17A-IL-17RA treatments. Func-
tional redundancies of such cytokines
have limited the impact of similar treat-
ments in models of experimental autoim-
mune encephalomyelitis and collagen-
induced arthritis.REFERENCES
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